Details for New Drug Application (NDA): 206229
✉ Email this page to a colleague
The generic ingredient in LILETTA is levonorgestrel. There are twenty drug master file entries for this compound. Thirty-four suppliers are listed for this compound. Additional details are available on the levonorgestrel profile page.
Summary for 206229
| Tradename: | LILETTA |
| Applicant: | Medicines360 |
| Ingredient: | levonorgestrel |
| Patents: | 4 |
Pharmacology for NDA: 206229
| Physiological Effect | Inhibit Ovum Fertilization |
Medical Subject Heading (MeSH) Categories for 206229
Suppliers and Packaging for NDA: 206229
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| LILETTA | levonorgestrel | SYSTEM;INTRAUTERINE | 206229 | NDA | Allergan, Inc. | 0023-5858 | 0023-5858-01 | 1 TRAY in 1 CARTON (0023-5858-01) / 1 INTRAUTERINE DEVICE in 1 TRAY |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | SYSTEM;INTRAUTERINE | Strength | 52MG | ||||
| Approval Date: | Feb 26, 2015 | TE: | RLD: | Yes | |||||
| Regulatory Exclusivity Expiration: | Jun 29, 2026 | ||||||||
| Regulatory Exclusivity Use: | TREATMENT OF HEAVY MENSTRUAL BLEEDING FOR UP TO 5 YEARS IN PATIENTS WHO CHOOSE INTRAUTERINE CONTRACEPTION AS THEIR METHOD OF CONTRACEPTION | ||||||||
| Patent: | 10,028,858 | Patent Expiration: | Mar 22, 2034 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
| Patented Use: | A METHOD FOR PREVENTION OF PREGNANCY | ||||||||
| Patent: | 11,090,186 | Patent Expiration: | Oct 24, 2033 | Product Flag? | Substance Flag? | Delist Request? | |||
| Patented Use: | A METHOD FOR PREVENTION OF PREGNANCY | ||||||||
Complete Access Available with Subscription
